Principal Financial Group Inc. Cuts Holdings in Qiagen (NYSE:QGEN)

Principal Financial Group Inc. lowered its stake in shares of Qiagen (NYSE:QGEN) by 12.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 14,464 shares of the company’s stock after selling 1,973 shares during the quarter. Principal Financial Group Inc.’s holdings in Qiagen were worth $659,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. PEAK6 Investments LLC lifted its stake in Qiagen by 270.0% during the first quarter. PEAK6 Investments LLC now owns 7,925 shares of the company’s stock worth $341,000 after purchasing an additional 12,587 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Qiagen by 13.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 91,763 shares of the company’s stock worth $3,945,000 after buying an additional 10,683 shares in the last quarter. CWM LLC grew its position in Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after acquiring an additional 269 shares during the last quarter. SG Americas Securities LLC raised its stake in shares of Qiagen by 14.2% during the second quarter. SG Americas Securities LLC now owns 496,951 shares of the company’s stock worth $20,420,000 after acquiring an additional 61,815 shares in the last quarter. Finally, Baader Bank Aktiengesellschaft lifted its holdings in shares of Qiagen by 88.0% in the 2nd quarter. Baader Bank Aktiengesellschaft now owns 37,602 shares of the company’s stock worth $1,540,000 after acquiring an additional 17,602 shares during the last quarter. 70.00% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Robert W. Baird increased their target price on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a research note on Thursday, October 17th. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.88.

Qiagen Stock Up 1.1 %

NYSE QGEN opened at $42.78 on Friday. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The stock has a market capitalization of $9.76 billion, a PE ratio of 109.69, a PEG ratio of 3.28 and a beta of 0.41. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.17 and a quick ratio of 1.89. The business’s 50-day moving average is $43.43 and its 200 day moving average is $43.72.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.